Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $10.00 Consensus Price Target from Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has been assigned an average recommendation of “Hold” from the nine research firms that are presently covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $10.00.

ZNTL has been the subject of several analyst reports. Guggenheim reduced their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a report on Friday, November 15th. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Erste Asset Management GmbH acquired a new position in shares of Zentalis Pharmaceuticals in the third quarter valued at $37,000. Paloma Partners Management Co bought a new stake in Zentalis Pharmaceuticals in the third quarter valued at $37,000. Aigen Investment Management LP bought a new stake in Zentalis Pharmaceuticals in the third quarter valued at $41,000. Capstone Investment Advisors LLC bought a new stake in Zentalis Pharmaceuticals in the third quarter valued at $48,000. Finally, China Universal Asset Management Co. Ltd. grew its position in Zentalis Pharmaceuticals by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock valued at $50,000 after acquiring an additional 5,333 shares during the period.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ ZNTL opened at $2.24 on Friday. The stock has a market cap of $159.62 million, a price-to-earnings ratio of -0.90 and a beta of 1.86. The business has a 50 day simple moving average of $3.17 and a 200 day simple moving average of $3.38. Zentalis Pharmaceuticals has a 52 week low of $2.16 and a 52 week high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.36. On average, analysts predict that Zentalis Pharmaceuticals will post -2.48 EPS for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.